Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 3/20 | 0.47 |
| ▸ | SLC16A1 | P53985 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597887 | 1.00 | SLC16A3 (0.47) | SLC16A3SLC16A1EGFRKDM4ECISD1 | |
| SCHEMBL14540647 | 1.00 | SLC16A3 (0.47) | SLC16A3SLC16A1EGFRKDM4ECISD1 | |
| SCHEMBL16301917 | 0.88 | MAPT (0.51) | EGFRKDM4EALDH1A1HPGDGPR35 | |
| SCHEMBL12305833 | 0.85 | SLC16A3 (0.43) | SLC16A3SLC16A1EGFRKDM4ECISD1 | |
| SCHEMBL23373774 | 0.84 | ALDH1A1 (0.49) | SLC16A3SLC16A1EGFRKDM4EALDH1A1 | |
| SCHEMBL10253234 | 0.84 | ALDH1A1 (0.44) | EGFRKDM4EALDH1A1HPGDRAD52 | |
| SCHEMBL597755 | 0.81 | KMT2A (0.55) | EGFRKDM4ECISD1ALDH1A1CYP3A4 | |
| SCHEMBL14703464 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HPGDKMT2ARXFP1 | |
| SCHEMBL15491206 | 0.78 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL1779715 | 0.77 | APP (0.53) | KDM4EALDH1A1CYP3A4HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4427033-B1 | METHOD FOR QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA BIOTECH GMBH (DE) | 2026-05-20 | — | — | EP | claimed |
| CN-119688656-A | Fluorescence detection method for amylase activity, application and microfluidic detection device | 上海交通大学医学院附属瑞金医院 | 2025-03-25 | — | — | CN | claimed |
| EP-4427033-A1 | METHOD FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA Biotech GmbH (DE) | 2024-09-11 | — | — | EP | claimed |
| CN-117229285-B | Synthesis and application of fluorescent probe for simultaneously distinguishing and detecting homocysteine and amyloid oligomer | 湖南师范大学 | 2024-07-16 | — | — | CN | claimed |
| CN-116625995-A | Application of 9- (2-carboxyl-2-cyanovinyl) julolidine in analysis of content of direct and amylopectin and ratio thereof | 中国农业大学 | 2023-08-22 | — | — | CN | claimed |
| EP-4211264-A1 | COMPOSITIONS AND METHODS FOR DETECTING AN ABASIC SITE OF A NUCLEIC ACID | Illumina, Inc. (US) | 2023-07-19 | — | — | EP | claimed |
| WO-2023079052-A1 | METHOD FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA BIOTECH GMBH (DE) | 2023-05-11 | — | — | WO | claimed |
| CN-115803451-A | Compositions and methods for detecting abasic sites of nucleic acids | 伊鲁米纳公司 | 2023-03-14 | — | — | CN | claimed |
| EP-2802871-B1 | CHARACTERIZATION OF SUBVISIBLE PARTICLES USING A PARTICLE ANALYZER | TAKEDA PHARMACEUTICALS CO (JP) | 2022-07-27 | — | — | EP | claimed |
| CN-114444568-A | Unsatisfied reason tracing method based on improved clustering algorithm | 福建新大陆软件工程有限公司 | 2022-05-06 | — | — | CN | claimed |
| WO-2022056169-A1 | COMPOSITIONS AND METHODS FOR DETECTING AN ABASIC SITE OF A NUCLEIC ACID | ILLUMINA, INC (US) | 2022-03-17 | — | — | WO | claimed |
| EP-4427033-B1 | METHOD FOR QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA BIOTECH GMBH (DE) | 2026-05-20 | — | — | EP | disclosed |
| US-12613246-B2 | Fluorescent probe and protein labeling method | FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-12596125-B2 | Nano-rheological biomarkers for early and improved follow-up of pathologies associated to RBC deformability alteration | ALCEDIAG (FR) | 2026-04-07 | — | — | US | disclosed |
| US-12392782-B2 | Characterization of protein binding to per- and polyfluoroalkyl substances | NORTH CAROLINA STATE UNIVERSITY (US) | 2025-08-19 | — | — | US | disclosed |
| US-20100059740-A1 | POLYMERIC ANIONS/CATIONS | MERCK PATENT GMBH (DE) | 2010-03-11 | — | — | US | disclosed |
| EP-1311001-B1 | DYE-SENSITIZED PHOTOELECTRIC TRANSDUCER | NIPPON KAYAKU KK (JP) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008087031-A1 | POLYMERIC ANIONS/CATIONS | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | WO | disclosed |
| US-20080110497-A1 | Modified Titanium Oxide Microparticle and Photoelectric Transducer Making Use of the Same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-05-15 | — | — | US | disclosed |
| US-20080110497-A1 | Modified Titanium Oxide Microparticle and Photoelectric Transducer Making Use of the Same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12613246-B2 | Fluorescent probe and protein labeling method | CYFIP1, IK, CYFIP2 | SLC16A3 4858/4885SLC16A1 4354/4885EGFR 2822/4885 |
| US-12596125-B2 | Nano-rheological biomarkers for early and improved follow-up of pathologies associated to RBC deformability alteration | SPTBN1, MB, HBZ | SLC16A3 3722/4885SLC16A1 3819/4885EGFR 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.